Zhejiang CONBA Pharmaceutical Co.,Ltd. announced that it has received CNY 1.093 billion in funding from Shanghai Guoxin Investment Development Co. Ltd., HuaAn Future Asset Management Co., Ltd., CCB Principal Asset Management Co., Ltd., Hangzhou Shengye Printing Co., Ltd., Goldstate Capital Fund Management Co., Ltd., Caitong Securities Asset Management Ltd.
January 10, 2018
Share
On January 10, 2018, Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) closed the transaction. The company amended the transactions. The company issued 156,590,200 shares at a price of CNY 6.98 per share for gross proceeds of CNY 1,092,999,596. The transaction will included participation from Shanghai Guoxin Investment Development Co. Ltd. for 17,191,900 shares for gross proceeds of CNY 119,999,462, HuaAn Future Asset Management (Shanghai) Co., Ltd. for 18,624,600 shares for gross proceeds of CNY 129,999,708, CCB Principal Asset Management Co., Ltd. (SZSE:165317) for 28,653,200 shares for gross proceeds of CNY 199,999,336, Hangzhou Shengye Printing Co., Ltd. 18,624,600 shares for gross proceeds of CNY 129,999,708, Goldstate Capital Fund Management Co., Ltd. for 59,455,500 shares for gross proceeds of CNY 414,999,390 , Caitong Securities Asset Management Ltd. for 14,040,400 shares for gross proceeds of CNY 98,001,992. The share registration procedures for the newly issued shares were completed with the China Securities Depository and Clearing Co., Ltd.
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
Zhejiang CONBA Pharmaceutical Co.,Ltd. announced that it has received CNY 1.093 billion in funding from Shanghai Guoxin Investment Development Co. Ltd., HuaAn Future Asset Management Co., Ltd., CCB Principal Asset Management Co., Ltd., Hangzhou Shengye Printing Co., Ltd., Goldstate Capital Fund Management Co., Ltd., Caitong Securities Asset Management Ltd.
ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD. 
